NASDAQ:ADTX Aditxt (ADTX) Stock Price, News & Analysis $0.45 0.00 (-0.67%) (As of 01:30 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Aditxt alerts: Email Address About Aditxt Stock (NASDAQ:ADTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aditxt alerts:Sign Up Key Stats Today's Range$0.42▼$0.4750-Day Range$0.44▼$2.3252-Week Range$0.42▼$24.00Volume153,384 shsAverage Volume1.05 million shsMarket Capitalization$891,318.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. It is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.Read More… Musk Says ‘Dollar Will Be Worth Nothing…’ (Ad)Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…All you have to do is claim your free ticket to the event now… Aditxt Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 24th PercentileAditxt scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Aditxt.Read more about Aditxt's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioAditxt has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aditxt's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.72% of the float of Aditxt has been sold short.Short Interest Ratio / Days to CoverAditxt has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aditxt has recently decreased by 96.18%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAditxt does not currently pay a dividend.Dividend GrowthAditxt does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.72% of the float of Aditxt has been sold short.Short Interest Ratio / Days to CoverAditxt has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aditxt has recently decreased by 96.18%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News Sentiment1.43 News SentimentAditxt has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aditxt this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for ADTX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Aditxt to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aditxt insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.23% of the stock of Aditxt is held by insiders.Percentage Held by InstitutionsOnly 15.54% of the stock of Aditxt is held by institutions.Read more about Aditxt's insider trading history. Receive ADTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aditxt and its competitors with MarketBeat's FREE daily newsletter. Email Address ADTX Stock News HeadlinesInvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Seeks Grant Funding to Advance Early Detection, Management of Prostate CancerSeptember 5, 2024 | msn.comInvestorNewsBreaks – Aditxt (NASDAQ: ADTX) Announces Participation at H.C. Wainwright 26th Annual Global Investment ConferenceAugust 29, 2024 | msn.comWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.September 17, 2024 | Porter & Company (Ad)Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024August 29, 2024 | businesswire.comEvofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral SolutionAugust 20, 2024 | prnewswire.comBioMedNewsBreaks — Evofem Biosciences Inc. (EVFM) Releases Second-Quarter 2024 Financial Results, Company UpdateAugust 14, 2024 | msn.comAditxt shareholders approve strategic proposalsAugust 14, 2024 | investing.comAditxt Announces the Successful Passage of all Proposals at Recent Annual Shareholders' Meeting, Setting the Stage for 2024 and 2025 Strategic PlansAugust 14, 2024 | stockhouse.comSee More Headlines ADTX Stock Analysis - Frequently Asked Questions How have ADTX shares performed this year? Aditxt's stock was trading at $6.63 at the beginning of the year. Since then, ADTX stock has decreased by 93.2% and is now trading at $0.45. View the best growth stocks for 2024 here. How were Aditxt's earnings last quarter? Aditxt, Inc. (NASDAQ:ADTX) posted its earnings results on Monday, August, 19th. The company reported ($4.19) earnings per share for the quarter. The company earned $0.04 million during the quarter. Aditxt had a negative net margin of 5,016.31% and a negative trailing twelve-month return on equity of 615.43%. When did Aditxt's stock split? Aditxt shares reverse split on the morning of Friday, August 18th 2023. The 1-40 reverse split was announced on Friday, August 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are Aditxt's major shareholders? Top institutional shareholders of Aditxt include Concourse Financial Group Securities Inc.. Insiders that own company stock include Paribas Securities Corp Bnp and Amro A Albanna. View institutional ownership trends. How do I buy shares of Aditxt? Shares of ADTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Aditxt own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aditxt investors own include Tesla (TSLA), Dynavax Technologies (DVAX), Boeing (BA), CrowdStrike (CRWD), Genius Brands International (GNUS), Nikola (NKLA) and Block (SQ). Company Calendar Last Earnings8/19/2024Today9/17/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADTX CUSIPN/A CIK1726711 Webwww.aditxt.com Phone650-870-1200FaxN/AEmployees60Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,380,000.00 Net Margins-5,016.31% Pretax Margin-17,250.94% Return on Equity-615.43% Return on Assets-157.59% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.05 Sales & Book Value Annual Sales$329,739.00 Price / Sales2.77 Cash FlowN/A Price / Cash FlowN/A Book Value$67.18 per share Price / Book0.01Miscellaneous Outstanding Shares1,994,000Free Float1,969,000Market Cap$913,451.40 OptionableNo Data Beta1.20 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (NASDAQ:ADTX) was last updated on 9/17/2024 by MarketBeat.com Staff From Our PartnersBiden's Executive Order, Dems Digital Money Legislation, First Step ToDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredWar on Elon Escalates… One company holds a near-total monopoly on this technology. Elon Musk is one of the few people who knows th...Porter & Company | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Altcoin for September 2024With thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aditxt, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aditxt With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.